Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery,
chemotherapy, target therapy, and radiotherapy. However, 25–50% of patients experience …

Soft-tissue sarcomas (STS) are a group of rare, heterogeneous, and aggressive tumors, with
high metastatic risk and relatively few efficient systemic therapies. In the quest for new …

This article provides a literature review of the use of MRI in monitoring the treatment
response of soft tissue sarcomas. The basic classification and physiology of soft tissue …

Purpose The purpose of this study was to clarify the prognostic significance of lymphocyte
infiltration in soft tissue sarcomas (STS). Prognostic markers in potentially curable STS …

Tumor hypoxia is significant in promoting tumor progression and resistance to therapy, and
hypoxia‑inducible factor 1α (HIF‑1α) is essential in the adaptive response of cells to hypoxia …

High‑grade soft‑tissue sarcoma (STS) is a highly malignant neoplasm with a poor overall
prognosis. Numerous prognostic factors determine tumor progression and patient outcomes …

Background The purpose of this study was to clarify the prognostic significance of
peritumoral lymphocyte infiltration in the capsule of soft tissue sarcomas (STS). Multiple …

Abstract BACKGROUND. CD100, a class IV semaphorin, promotes angiogenesis, invasive
growth, proliferation, and antiapoptosis of cancer cells in vitro. The expression of CD100 in …

Purpose: Soft tissue sarcoma (STS) is a rare heterogeneous malignancy. Overall survival
has been stagnant for decades, primarily because systemic therapies are ineffective versus …

Background Prognostic markers in curable STS may have the potential to guide therapy
after surgical resection. The purpose of this study was to clarify the prognostic impact of the …